The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kirilochev O.O.

Astrakhan State Medical University, Astrakhan, Russia;
Astrakhan Regional Clinical Psychiatric Hospital, Astrakhan, Russia

Umerova A.R.

Astrakhan State Medical University, Astrakhan, Russia

Safety of psychopharmacotherapy: a clinical and pharmacological approach

Authors:

Kirilochev O.O., Umerova A.R.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10): 127‑133

DOI: 10.17116/jnevro2019119101127

Read: 6651 times

Download PDF (RU)
Contact the author
Table of contents

SAFETY OF PSYCHOPHARMACOTHERAPY: A CLINICAL AND PHARMACOLOGICAL APPROACH
SAFETY OF PSYCHOPHARMACOTHERAPY: A CLINICAL AND PHARMACOLOGICAL APPROACH

To cite this article:

Kirilochev OO, Umerova AR. Safety of psychopharmacotherapy: a clinical and pharmacological approach. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10):127‑133. (In Russ.)
https://doi.org/10.17116/jnevro2019119101127

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Therapeutic targets of adolescent depression with atte­nuated symptoms of schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):69-74
The effect of psychopharmacological load on various aspe­cts of the condition in patients with depressive syndrome during remi­ssion. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):69-76
Abstract:

The prescription of psychotropic drugs requires a thorough assessment not only of the effectiveness of pharmacotherapy, but also of its safety. It is an essential component of the rational treatment of patients with mental disorders. Most of adverse drug reactions are predictable and, accordingly, preventable. The solution to problem of adverse drug reactions prevention is feasible thanks to the interdisciplinary approach, in which the skills and methods of clinical pharmacology can be used in psychiatry. This literature review covers the current possibilities for monitoring the safety of psychopharmacotherapy.

Keywords:

psychopharmacotherapy
drug safety
adverse drug reactions

Authors:

Kirilochev O.O.

Astrakhan State Medical University, Astrakhan, Russia;
Astrakhan Regional Clinical Psychiatric Hospital, Astrakhan, Russia

Umerova A.R.

Astrakhan State Medical University, Astrakhan, Russia

Close metadata

References:

  1. Kozlovsky V. Rational pharmacotherapy in psychiatry. Vrach. 2012;12:21-25. (In Russ.)
  2. Üçok A, Gaebel W. Side effects of atypical antipsychotics: a brief overview. World Psychiatry. 2008;7(1):58-62. https://doi.org/10.1002/j.2051-5545.2008.tb00154.x
  3. Burashnikova IS, Minnekeeva KA, Sychev DA, Polivanov VA, Semenikhin DG. Comparative analysis of adverse reactions during use of typical and atypical antipsychotics. Vestnik Roszdravnadzora. 2016;5:109-113. (In Russ.)
  4. Parks KA, Parks CG, Yost JP, Bennett JI, Onwuameze OE. Acute Blood Pressure Changes Associated With Antipsychotic Administration to Psychiatric Inpatients. Prim care companion CNS Disord. 2018;20(4):18m02299. https://doi.org/10.4088/PCC.18m02299
  5. Arana GW. An overview of side effects caused by typical antipsychotics. J Clin Psychiatry. 2000;61(suppl 8):5-11; discussion 12-13. PMID: 10811237.
  6. Von Euler M, Eliasson E, Öhlén G, Bergman U. Adverse drug reactions causing hospitalization can be monitored from computerized medical records and thereby indicate the quality of drug utilization. Pharmacoepidemiol Drug Saf. 2006;15(3):179-184. https://doi.org/10.1002/pds.1154
  7. Robert Swanson J, Jones G, Krasselt W, Denmark L, Ratti F. Death of Two Subjects Due to Imipramine and Desipramine Metabolite Accumulation During Chronic Therapy: A Review of the Literature and Possible Mechanisms. J Forensic Sci. 1997;42(2):14124J. https://doi.org/10.1520/jfs14124j
  8. Shikh EV, Ismagilov AD, Sizova ZhM, Demidova OA. Bezopasnost kombinirovannoy farmakoterapii u patsientov pozhilogo vozrasta. Vedomosti Nauchnogo Centra E’kspertizy’ Sredstv Medicinskogo Primeneniya. 2017;7(1):47-54. (In Russ.)
  9. Fomin E, Baichorov I, Shikh E, Sizova Zh. Vrach. 2014;(1):13-17. (In Russ.)
  10. Furman NV, Shmatova SS. Clinical significance of druginduced intervals QT and QTc prolongation. Rational Pharmacotherapy in Cardiology. 2013;9(3):311-315. https://doi.org/10.20996/1819-6446-2013-9-3-311-315
  11. Straus S, Bleumink G, Dieleman J, van der Lei J, ‘t Jong G, Kingma J, Sturkenboom M, Stricker B. Antipsychotics and the Risk of Sudden Cardiac Death. Arch Intern Med. 2004;164(12):1293. https://doi.org/10.1001/archinte.164.12.1293
  12. Van der Sijs H, Kowlesar R, Klootwijk A, Nelwan S, Vulto A, van Gelder T. Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol. 2009;67(3):347-354. https://doi.org/10.1111/j.1365-2125.2008.03357.x
  13. Woosley R, Romero K, Heise C, Gallo T, Tate J, Woosley R, Ward S. Adverse Drug Event Causality Analysis (ADECA): A Process for Evaluating Evidence and Assigning Drugs to Risk Categories for Sudden Death. Drug Saf. 2017;40(6):465-474. https://doi.org/10.1007/s40264-017-0519-0
  14. Gallego J, Nielsen J, De Hert M, Kane J, Correll C. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf. 2012;11(4):527-542. https://doi.org/10.1517/14740338.2012.683523
  15. Ajmal A, Joffe H, Nachtigall L. Psychotropic-Induced Hyperprolactinemia: A Clinical Review. Psychosomatics. 2014;55(1):29-36. https://doi.org/10.1016/j.psym.2013.08.008
  16. Grigg J, Worsley R, Thew C, Gurvich C, Thomas N, Kulkarni J. Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology (Berl). 2017;234(22):3279-3297. https://doi.org/10.1007/s00213-017-4730-6
  17. Mittal S, Prasad S, Ghosh A. Antipsychotic-induced hyperprolactinaemia: case studies and review. Postgrad Med J. 2017;94(1110):226-229. https://doi.org/10.1136/postgradmedj-2017-135221
  18. Khalil R, Richa S. Thyroid Adverse Effects of Psychotropic Drugs. Clin Neuropharmacol. 2011;34(6):248-255. https://doi.org/10.1097/wnf.0b013e31823429a7
  19. Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis. PLoS ONE. 2014;9(4):e94112. https://doi.org/10.1371/journal.pone.0094112
  20. Shrivastava A, Johnston M. Weight-Gain in Psychiatric Treatment: Risks, Implications, and Strategies for Prevention and Management. Mens Sana Monogr. 2010;8(1):53. https://doi.org/10.4103/0973-1229.58819
  21. Tek C, Kucukgoncu S, Guloksuz S, Woods S, Srihari V, Annamalai A. Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications. Early Interv Psychiatry. 2015;10(3):193-202. https://doi.org/10.1111/eip.12251
  22. Cockcroft D, Gault H. Prediction of Creatinine Clearance from Serum Creatinine. Nephron. 1976;16(1):31-41. https://doi.org/10.1159/000180580
  23. Levey A, Coresh J, Greene T, Stevens L, Zhang Y, Hendriksen S, Kusek J, Van Lente F. Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate. Ann Intern Med. 2006;145(4):247. https://doi.org/10.7326/0003-4819-145-4-200608150-00004
  24. Levey A, Stevens L, Schmid C, Zhang Y, Castro A, Feldman H, Kusek J, Eggers P, Van Lente F, Greene T, Coresh J. A New Equation to Estimate Glomerular Filtration Rate. Ann Intern Med. 2009;150(9):604. https://doi.org/10.7326/0003-4819-150-9-200905050-00006
  25. Mitchell P. Therapeutic drug monitoring of psychotropic medications. Br J Clin Pharmacol. 2001;49(4):303-312. https://doi.org/10.1046/j.1365-2125.2000.00174.x
  26. Greenberg R, Melloni C, Wu H, Gonzalez D, Ku L, Hill K, Hornik C, Cohen-Wolkowiez M, Guptill J. Therapeutic Index Estimation of Antiepileptic Drugs. Clin Neuropharmacol. 2016;39(5):232-240. https://doi.org/10.1097/wnf.0000000000000172
  27. Sychev DA, Otdelenov VA, Denisenko NP, Smirnov VV. The study of the activity of isoenzymes of cytochrome P450 for the prediction of drug-drug interactions of medicines in terms of polypharmacy. Farmakogenetika i Farmakogenomika. 2016;2:4-11. (In Russ.)
  28. Schoretsanitis G, Spina E, Hiemke C, de Leon J. A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. Expert Rev Clin Pharmacol. 2017;10(9):965-981. https://doi.org/10.1080/17512433.2017.1345623
  29. Spina E, Hiemke C, de Leon J. Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2016;12(4):407-422. https://doi.org/10.1517/17425255.2016.1154043
  30. Hiemke C, Bergemann N, Clement H, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mössner R, Müller M, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia M, Stegmann B, Steimer W, Stingl J, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2017;51(01/02):9-62. https://doi.org/10.1055/s-0043-116492
  31. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey G. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1). https://doi.org/10.1186/s12877-017-0621-2
  32. Petrova NN, Dorofeikova MV. Antipsychotic polypharmacy: pros and cons. Sovremennaya Terapiya Psixicheskix Rasstrojstv. 2016;1:11-16. (In Russ.)
  33. Frois C, Guerin A, Saraogi A, Panish J, Dirani R. Perceptions and prescribing considerations among US psychiatrists regarding drug—drug interactions associated with oral atypical antipsychotics. Curr Med Res Opin. 2010;26(12):2735-2744. https://doi.org/10.1185/03007995.2010.530159
  34. Liperoti R, Sganga F, Landi F, Topinkova E, Denkinger M, van der Roest H, Foebel A, Finne-Soveri H, Bernabei R, Onder G. Antipsychotic Drug Interactions and Mortality Among Nursing Home Residents With Cognitive Impairment. J Clin Psychiatry. 2017;78(01):76-82. https://doi.org/10.4088/jcp.15m10303
  35. Goren JL, Dinh TA. Psychotropics and sudden cardiac death. R I Med J. 2013;96(3):38-41. PMID: 23641438.
  36. Takeuchi H, Suzuki T, Remington G, Uchida H. Antipsychotic Polypharmacy and Corrected QT Interval: A Systematic Review. The Canadian Journal of Psychiatry. 2015;60(5):215-222. https://doi.org/10.1177/070674371506000503
  37. Windfuhr K, Turnbull P, While D, Swinson N, Mehta H, Hadfield K, Hiroeh U, Watkinson H, Dixon C, Flynn S, Thomas S, Lewis G, Ferrier I, Amos T, Skapinakis P, Shaw J, Kapur N, Appleby L. The incidence and associated risk factors for sudden unexplained death in psychiatric in-patients in England and Wales. Journal of Psychopharmacology. 2010;25(11):1533-1542. https://doi.org/10.1177/0269881110379288
  38. Gallego J, Bonetti J, Zhang J, Kane J, Correll C. Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012;138(1):18-28. https://doi.org/10.1016/j.schres.2012.03.018
  39. Leckman-Westin E, Kealey E, Gupta N, Chen Q, Gerhard T, Crystal S, Olfson M, Finnerty M. Validation of a claims-based antipsychotic polypharmacy measure. Pharmacoepidemiol Drug Saf. 2014;23(6):628-635. https://doi.org/10.1002/pds.3609
  40. Correll C, Rummel-Kluge C, Corves C, Kane J, Leucht S. Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials. Schizophr Bull. 2008;35(2):443-457. https://doi.org/10.1093/schbul/sbn018
  41. Goff D, Freudenreich O. Focus on Polypharmacy in schizophrenia: does anyone truly benefit? Int J Neuropsychopharmacol. 2004;7(2):109-111. https://doi.org/10.1017/s1461145704004183
  42. Megna J, Kunwar A, Mahlotra K, Sauro M, Devitt P, Rashid A. A Study of Polypharmacy with Second Generation Antipsychotics in Patients with Severe and Persistent Mental Illness. J Psychiatr Pract. 2007;13(2):129-137. https://doi.org/10.1097/01.pra.0000265773.03756.3e
  43. Centorrino F, Masters G, Talamo A, Baldessarini R, Öngür D. Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics. Human Psychopharmacology: Clinical and Experimental. 2012;27(5):521-526. https://doi.org/10.1002/hup.2257
  44. Misawa F, Shimizu K, Fujii Y, Miyata R, Koshiishi F, Kobayashi M, Shida H, Oguchi Y, Okumura Y, Ito H, Kayama M, Kashima H. Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study. BMC Psychiatry. 2011;11(1). https://doi.org/10.1186/1471-244x-11-118
  45. Tranulis C, Skalli L, Lalonde P, Nicole L, Stip E. Benefits and Risks of Antipsychotic Polypharmacy. Drug Saf. 2008;31(1):7-20. https://doi.org/10.2165/00002018-200831010-00002
  46. Lelliott P, Paton C, Harrington M, Konsolaki M, Sensky T, Okocha C. The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. Psychiatric Bulletin. 2002;26(11):411-414. https://doi.org/10.1192/pb.26.11.411
  47. Hahn M, Reiff J, Hiemke C, Braus D. Drug-Drug-Interactions in Psychiatry. Psychiatr Prax. 2013;40(03):154-158. https://doi.org/10.1055/s-0032-1332831
  48. Ravyn D, Ravyn V, Lowney R, Nasrallah H. CYP450 Pharmacogenetic treatment strategies for antipsychotics: A review of the evidence. Schizophr Res. 2013;149(1-3):1-14. https://doi.org/10.1016/j.schres.2013.06.035
  49. Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug—drug interactions. Expert Opin Drug Saf. 2011;11(1):83-94. https://doi.org/10.1517/14740338.2012.631910
  50. Teixeira J, Crozatti M, dos Santos C, Romano-Lieber N. Potential Drug-Drug Interactions in Prescriptions to Patients over 45 Years of Age in Primary Care, Southern Brazil. PLoS ONE. 2012;7(10):e47062. https://doi.org/10.1371/journal.pone.0047062
  51. Namazi S, Kheshti R, Aalipour M. A comparison of five common drug—drug interaction software programs regarding accuracy and comprehensiveness. J Res Pharm Pract. 2016;5(4):257. https://doi.org/10.4103/2279-042x.192461
  52. Vonbach P, Dubied A, Krähenbühl S, Beer J. Evaluation of frequently used drug interaction screening programs. Pharmacy World & Science. 2008;30(4):367-374. https://doi.org/10.1007/s11096-008-9191-x
  53. ACOG Practice Bulletin No. 92: Use of Psychiatric Medications During Pregnancy and Lactation. Obstetrics & Gynecology. 2008;111(4):1001-1020. https://doi.org/10.1097/aog.0b013e31816fd910
  54. Ushkalova AV, Ushkalova EA. Treatment of mental disorders in pregnancy. Farmateka. 2013;263(10):76-85. (In Russ.)
  55. Kronenfeld N, Berlin M, Shaniv D, Berkovitch M. Use of Psychotropic Medications in Breastfeeding Women. Birth Defects Res. 2017;109(12):957-997. https://doi.org/10.1002/bdr2.1077
  56. Rapoport J. Pediatric psychopharmacology: too much or too little? World Psychiatry. 2013;12(2):118-123. https://doi.org/10.1002/wps.20028
  57. Southammakosane C, Schmitz K. Pediatric Psychopharmacology for Treatment of ADHD, Depression, and Anxiety. Pediatrics. 2015;136(2):351-359. https://doi.org/10.1542/peds.2014-1581
  58. Ushkalova E, Tkacheva O, Runikhina N, Chukhareva N, Bevz A. Features of pharmacotherapy in the elderly patients. Introduction to the problem. Rational Pharmacotherapy in Cardiology. 2016;12(1):94-100. https://doi.org/10.20996/1819-6446-2016-12-1-94-100
  59. Davis T, Sanchez-Covarubias L, Tome M. P-glycoprotein Trafficking as a Therapeutic Target to Optimize CNS Drug Delivery. Pharmacology of the Blood Brain Barrier: Targeting CNS Disorders. 2014;25-44. https://doi.org/10.1016/bs.apha.2014.06.009
  60. Mattappalil A, Mergenhagen K. Neurotoxicity with Antimicrobials in the Elderly: A Review. Clin Ther. 2014;36(11):1489-1511.e4. https://doi.org/10.1016/j.clinthera.2014.09.020
  61. Gray S, Hanlon J. Anticholinergic medication use and dementia: latest evidence and clinical implications. Ther Adv Drug Saf. 2016;7(5):217-224. https://doi.org/10.1177/2042098616658399
  62. Naples J, Marcum Z, Perera S, Gray S, Newman A, Simonsick E, Yaffe K, Shorr R, Hanlon J. Concordance Between Anticholinergic Burden Scales. J Am Geriatr Soc. 2015;63(10):2120-2124. https://doi.org/10.1111/jgs.13647
  63. Sychev DA, Orekhov RE. Anticholinergic cognitive burden scale. Klinicheskaya Farmakologiya i Terapiya. 2016;25(4):81-84. (In Russ.)
  64. Durán C, Azermai M, Vander Stichele R. Systematic review of anticholinergic risk scales in older adults. Eur J Clin Pharmacol. 2013;69(7):1485-1496. https://doi.org/10.1007/s00228-013-1499-3
  65. Lee M, Hanger H. Audit of anticholinergic medication changes in older hospitalised patients using the Anticholinergic Drug Scale. Intern Med J. 2017;47(6):689-694. https://doi.org/10.1111/imj.13402
  66. Lertxundi U, Domingo-Echaburu S, Hernandez R, Peral J, Medrano J. Expert-based drug lists to measure anticholinergic burden: similar names, different results. Psychogeriatrics. 2013;13(1):17-24. https://doi.org/10.1111/j.1479-8301.2012.00418.x
  67. Salahudeen M, Duffull S, Nishtala P. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr. 2015;15(1). https://doi.org/10.1186/s12877-015-0029-9
  68. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015;63(11):2227-2246. https://doi.org/10.1111/jgs.13702
  69. O’Mahony D, O’Sullivan D, Byrne S, O’Connor M, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2014;44(2):213-218. https://doi.org/10.1093/ageing/afu145
  70. Ivashchenko DV, Kibitov AO, Sychev DA. Pharmacogenetics of antipsychotics in practice: a review of current evidence base and prospects of personalization in pharmacotherapy of schizophrenia. Psixicheskoe Zdorov’e. 2017;2:91-95. (In Russ.)
  71. Zubenko G, Sommer B, Cohen B. Pharmacogenetics in Psychiatry: A Companion, Rather Than Competitor, to Protocol-Based Care — Reply. JAMA Psychiatry. 2018;75(10):1090. https://doi.org/10.1001/jamapsychiatry.2018.2355
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.